Depression and breast cancer: research progress and prospects from an interdisciplinary perspective

Depression and breast cancer are two major health concerns in the medical field today. Not only do they mutually influence the risk of onset and disease progression, but they also collectively lead to poorer clinical outcomes and reduced quality of life.

This review elaborates on how depression, through the overactivation of the hypothalamic-pituitary-adrenal (HPA) axis, may be associated with persistently elevated levels of glucocorticoids (GCs). This, in turn, causes dysregulation of the sex hormone axis, prolactin imbalance, and insulin resistance, collectively promoting the initiation and progression of breast cancer.

Meanwhile, the depressive state may suppresses the function of immune cells such as T cells and natural killer (NK) cells, and promotes the release of pro-inflammatory cytokines, thereby impairing immune surveillance and creating a favorable environment for tumor growth. Furthermore, imbalances in tryptophan metabolism and gut microbiota dysbiosis exacerbate neuroimmune dysregulation, forming a vicious cycle.

In terms of treatment, standalone biomedical or psychological interventions have limited efficacy, necessitating an interdisciplinary and integrated approach. Pharmacological treatment requires attention to drug interactions between antidepressants and breast cancer medications such as tamoxifen.